Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer
We present a case of a 59-year-old male with a confirmed diagnosis of small-cell lung cancer (SCLC). He had progressive disease even after four cycles of cisplatin and etoposide chemotherapy and 21 cycles of radiation. He was therefore started on immunotherapy with nivolumab every 2 weeks and ipilim...
Saved in:
Main Authors: | Kavita Agrawal, Nirav Agrawal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Neurological Medicine |
Online Access: | http://dx.doi.org/10.1155/2019/5353202 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pseudomyopathic Changes in Needle Electromyography in Lambert-Eaton Myasthenic Syndrome
by: Teppei Komatsu, et al.
Published: (2013-01-01) -
Myasthenia gravis and Lambert-Eaton myasthenic syndrome: treatment options and guidance for management during COVID-19 pandemic
by: A. Klimašauskienė, et al.
Published: (2020-06-01) -
Using Intravenous Inmunoglobulin in an Atypical Case of Lambert Eaton Síndrome.
by: Erélido Hernández Valero, et al.
Published: (2007-04-01) -
Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01) -
Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab
by: Adnan Kilani, et al.
Published: (2023-01-01)